NASDAQ:VRCA

Verrica Pharmaceuticals Stock Forecast, Price & News

$12.69

-1.00 (-7.30 %)

(As of 04/16/2021 04:00 PM ET)

Add

Compare

Today's Range

$12.50

Now: $12.69▼

$13.93

50-Day Range

$13.24

MA: $14.75▼

$17.46

52-Week Range

$6.02

Now: $12.69▼

$18.42

Volume112,795 shs

Average Volume107,625 shs

Market Capitalization$322.85 million

P/E RatioN/A

Dividend YieldN/A

Beta2.3

Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company has a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica Pharmaceuticals Inc. was founded in 2013 and is headquartered in West Chester, Pennsylvania.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VRCA

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.verrica.com

Phone484-453-3300

Employees17

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio2.15

Quick Ratio2.15

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.52 per share

Price / Book5.04

Profitability

EPS (Most Recent Fiscal Year)($1.13)

Net Income$-28,210,000.00

Net MarginsN/A

Return on Equity-54.53%

Return on Assets-40.42%

Miscellaneous

Outstanding Shares25,441,000

Market Cap$322.85 million

Next Earnings Date5/6/2021 (Estimated)

OptionableNot Optionable

Headlines

Verrica Pharmaceuticals' (VRCA) "Buy" Rating Reiterated at Needham & Company LLC
April 14, 2021 | americanbankingnews.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Expected to Announce Earnings of -$0.35 Per Share
April 6, 2021 | americanbankingnews.com

Zacks: Analysts Expect Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Will Post Earnings of -$0.35 Per Share
April 6, 2021 | americanbankingnews.com

Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
April 6, 2021 | finance.yahoo.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update
March 31, 2021 | americanbankingnews.com

Contrasting Esperion Therapeutics (NASDAQ:ESPR) & Verrica Pharmaceuticals (NASDAQ:VRCA)
March 29, 2021 | americanbankingnews.com

Insider Buying: Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Director Acquires 739,830 Shares of Stock
March 29, 2021 | americanbankingnews.com

Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association
March 29, 2021 | finance.yahoo.com

Verrica, Windtree complete $30M public stock offerings
March 26, 2021 | bizjournals.com

Verrica Announces Pricing of Public Offering of Common Stock
March 23, 2021 | finance.yahoo.com

Verrica Announces Proposed Public Offering of Common Stock
March 22, 2021 | finance.yahoo.com

VERRICA PHARMAC. DL-,0001 (1NE.BE)
March 21, 2021 | in.finance.yahoo.com

Verrica Pharma shares rise 6% on licensing deal for VP-102 in Japan
March 18, 2021 | seekingalpha.com

Verrica Pharmaceuticals finalizes multimillion-dollar product licensing deal
March 17, 2021 | bizjournals.com

Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan
March 17, 2021 | finance.yahoo.com

Verrica Pharmaceuticals could reel in $70M after Japanese firm Torii exercises option
March 5, 2021 | bizjournals.com

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results
March 4, 2021 | finance.yahoo.com

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference
March 3, 2021 | finance.yahoo.com

Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference
February 23, 2021 | finance.yahoo.com

Vectoring Back In On Verrica Pharmaceuticals
February 19, 2021 | seekingalpha.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.64 out of 5 stars

Medical Sector

349th out of 2,025 stocks

Pharmaceutical Preparations Industry

161st out of 772 stocks

3.4 Analyst's Opinion

Consensus Rating
Verrica Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.75, Verrica Pharmaceuticals has a forecasted upside of 39.9% from its current price of $12.69.
Amount of Analyst Coverage
Verrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Verrica Pharmaceuticals has received 126 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Verrica Pharmaceuticals has received 144 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Verrica Pharmaceuticals has received 53.33% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Verrica Pharmaceuticals and other stocks. Vote “Outperform” if you believe VRCA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRCA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Verrica Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Verrica Pharmaceuticals does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verrica Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,912,492.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
40.20% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 33.97% of the stock of Verrica Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Verrica Pharmaceuticals are expected to decrease in the coming year, from ($1.73) to ($1.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Verrica Pharmaceuticals is -9.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Verrica Pharmaceuticals is -9.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Verrica Pharmaceuticals has a P/B Ratio of 5.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$12.69

-1.00 (-7.30 %)

(As of 04/16/2021 04:00 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.

Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

Is Verrica Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Verrica Pharmaceuticals stock.
View analyst ratings for Verrica Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Verrica Pharmaceuticals?

Wall Street analysts have given Verrica Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Verrica Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Verrica Pharmaceuticals?

Verrica Pharmaceuticals saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 1,120,000 shares, a decline of 24.3% from the February 28th total of 1,480,000 shares. Based on an average trading volume of 99,700 shares, the short-interest ratio is currently 11.2 days. Currently, 7.7% of the company's shares are short sold.
View Verrica Pharmaceuticals' Short Interest.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Verrica Pharmaceuticals.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) announced its quarterly earnings data on Wednesday, March, 3rd. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.10.
View Verrica Pharmaceuticals' earnings history.

How has Verrica Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VRCA shares have increased by 20.6% and is now trading at $12.69.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for VRCA?

4 equities research analysts have issued 1 year price targets for Verrica Pharmaceuticals' stock. Their forecasts range from $10.00 to $24.00. On average, they anticipate Verrica Pharmaceuticals' share price to reach $17.75 in the next year. This suggests a possible upside of 39.9% from the stock's current price.
View analysts' price targets for Verrica Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the following people:

Mr. Ted White, Pres, CEO & Director (Age 56, Pay $666.19k)
Mr. A. Brian Davis, Chief Financial Officer (Age 54, Pay $342.85k)
Mr. Joe Bonaccorso, Chief Commercial Officer (Age 57, Pay $528.11k)
Dr. Gary Goldenberg M.D., Chief Medical Officer (Age 44, Pay $55k)
Mr. Christopher G. Hayes, Chief Legal Officer, Sec. & Gen. Counsel (Age 57)
Mr. Eugene Scavola, Exec. VP of Technical Operations
Dr. Bradley J. Catalone MBA, Ph.D., Head of Drug Devel.

Who are some of Verrica Pharmaceuticals' key competitors?

Some companies that are related to Verrica Pharmaceuticals include COMPASS Pathways (CMPS), Shattuck Labs (STTK), Repare Therapeutics (RPTX), Dynavax Technologies (DVAX), Ocular Therapeutix (OCUL), Kronos Bio (KRON), Innoviva (INVA), Avid Bioservices (CDMO), Protagonist Therapeutics (PTGX), Phathom Pharmaceuticals (PHAT), Mersana Therapeutics (MRSN), Nkarta (NKTX), Y-mAbs Therapeutics (YMAB), Omeros (OMER) and Stoke Therapeutics (STOK).
View all of VRCA's competitors.

What other stocks do shareholders of Verrica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI) and Aeterna Zentaris (AEZS).

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $12.69.

How much money does Verrica Pharmaceuticals make?

Verrica Pharmaceuticals has a market capitalization of $322.85 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

How many employees does Verrica Pharmaceuticals have?

Verrica Pharmaceuticals employs 17 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is www.verrica.com.

Where are Verrica Pharmaceuticals' headquarters?

Verrica Pharmaceuticals is headquartered at 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]

This page was last updated on 4/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here